Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.28 USD
Change Today +0.12 / 1.95%
Volume 447.8K
ECYT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

endocyte inc (ECYT) Key Developments

Endocyte, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Endocyte, Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $12,000 compared to $17,274,000 a year ago. Loss from operations was $8,187,000 compared to $2,963,000 a year ago. Net loss was $8,081,000 compared to $2,902,000 a year ago. Basic and diluted loss per share was $0.19 compared to $0.08 a year ago. For the year, the company reported collaboration revenue of $70,353,000 compared to $64,871,000 a year ago. Income from operations was $5,026,000 compared to loss from operations of $18,342,000 a year ago. Net income was $5,459,000 compared to net loss of $18,032,000 a year ago. Basic and diluted earnings per share were $0.13 compared to basic and diluted loss per share of $0.50 a year ago.

Endocyte, Inc., Q4 2014 Earnings Call, Mar 02, 2015

Endocyte, Inc., Q4 2014 Earnings Call, Mar 02, 2015

Endocyte, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 02:35 PM

Endocyte, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 02:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Michael A. Sherman, Chief Financial Officer and Chief Operating Officer.

Endocyte, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:40 AM

Endocyte, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:40 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

Endocyte, Inc. Announces Unaudited Financial Results for the Third Quarter Ending Sept. 30, 2014

Endocyte, Inc. announced unaudited financial results for the third quarter ending Sept. 30, 2014. For the quarter, the company reported collaboration revenue of $16,600,000 against $3,904,000 a year ago. Loss from operations was $3,043,000 against $5,778,000 a year ago. Net loss was $3,041,000 or $0.08 per share basic and diluted against $5,675,000 or $0.14 per share basic and diluted a year ago. For the nine months, the company reported collaboration revenue of $47,597,000 against $70,341,000 a year ago. Loss from operations was $15,379,000 against income from operations of $13,213,000 a year ago. Net loss was $15,130,000 or $0.42 per share basic and diluted against net income of $13,540,000 or $0.33 per share diluted a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECYT:US $6.28 USD +0.12

ECYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECYT.
View Industry Companies
 

Industry Analysis

ECYT

Industry Average

Valuation ECYT Industry Range
Price/Earnings 47.1x
Price/Sales 3.7x
Price/Book 1.3x
Price/Cash Flow 47.3x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOCYTE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.